Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of COVID-19 Vaccines in Adolescents: Systematic Review of Randomized Controlled Studies and Observational Studies

  • Soo-Han Choi (Department of Pediatrics, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Su-Yeon Yu (Department of Pharmacy, College of Pharmacy, Kangwon National University) ;
  • Jimin Kim (Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency) ;
  • Miyoung Choi (Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency) ;
  • Youn Young Choi (Department of Pediatrics, National Medical Center) ;
  • Jae Hong Choi (Department of Pediatrics, Jeju National University School of Medicine) ;
  • Ki Wook Yun (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Young June Choe (Department of Pediatrics, Korea University Anam Hospital)
  • Received : 2022.12.29
  • Accepted : 2024.01.16
  • Published : 2024.04.25
Download PDF
⟨ Previous Next ⟩

Abstract

The number of pediatric coronavirus disease 2019 (COVID-19) cases worldwide are increasing compared to the early phase of the pandemic, along with highly transmissible severe acute respiratory syndrome coronavirus variant and the increase in adult COVID-19 vaccination. We conducted a rapid systematic review and meta-analysis of published randomized clinical trials (RCTs) of the COVID-19 vaccines and the observational retrospective studies on adverse events after COVID-19 vaccination in adolescents. Seventeen studies were finally included in this systematic review. Meta-analysis showed that although vaccination in adolescents was significantly effective to prevent COVID-19 infection in retrospective studies (risk ratio [RR], 0.29; 95% confidence interval [CI], 0.22-0.37; I2 =100%), however the effect of preventing COVID-19 infection was lower than in RCTs (RR, 0.05; 95% CI, 0.01-0.27). In five retrospective studies, the pooled estimated proportion of participants with myocarditis and/or pericarditis was 2.33 per 100,000 of the population (95% CI, 0.97-5.61 per 100,000). Sub-group analysis with sex and vaccine doses showed that male (5.35 per 100,000) and the second dose (9.71 per 100,000) had significantly higher incidence of myocarditis and/or pericarditis than female (1.09 per 100,000) and the first dose (1.61 per 100,000), respectively. Our study showed that mRNA COVID-19 vaccines in adolescent recipients were favorable and effective against COVID-19 in RCT as well as observational studies. The safety findings of BNT162b2 vaccine in adolescents were explored and we found the difference of safety according to sex and vaccine doses. The occurrence of adverse events after mRNA COVID-19 vaccination should be monitored.

본세계적으로 소아 코로나바이러스 감염 2019 (COVID-19) 환자 수가 질병 초기와 비교하여 증가하고 있으며, 이는 고도로 전염성이 있는 중증 급성 호흡기 증후군 코로나바이러스 변이와 성인 COVID-19 백신 접종 증가와 관련이 있다. 본 연구는 청소년 대상 COVID-19 백신 접종의 무작위 임상시험 (randomized controlled trial, RCT) 후향적 관찰연구를 대상으로 신속 체계적 문헌고찰과 메타 분석을 수행했다. 체계적 문헌고찰 결과, 17개의 연구가 최종적으로 포함되었다. 메타 분석 결과, 청소년 대상 예방접종은 후향적 관찰 연구에서 COVID-19 감염을 예방하는 데 유의미하게 효과적이었으나 (risk ratio [RR], 0.29; 95% confidence interval [CI], 0.22-0.37; I2=100%), RCT보다 COVID-19 감염을 예방하는 효과가 낮았다 (RR, 0.05; 95% CI, 0.01-0.27). 5개의 후향적 관찰 연구에서, 국민 10만 명당 심근염 및/또는 심낭염 비율은 2.33명 (95% CI, 0.97-5.61 명)이었다. 성별 및 백신 접종 횟수에 따른 하위 그룹 분석 결과, 남성 (국민 10만 명당 5.35 명) 및 두 번째 접종 (국민 10만 명당 9.71명)은 여성 (국민 10만 명당 1.09명) 및 첫 번째 접종 (국민 10만 명당 1.61명)보다 심근염 및/또는 심낭염 발생률이 유의하게 높았다. 본 연구에서는 청소년을 대상으로 mRNA COVID-19 백신을 접종하는 것은 RCT 및 관찰연구 모두에서 COVID-19에 대해 효과적이었다. 또한 청소년 대상 BNT162b2 백신의 안전성 결과를 탐색하였으며, 성별 및 백신 접종 횟수에 따른 안전성의 차이를 확인했다. 향후 mRNA COVID-19 예방접종 후 부작용 발생은 계속 모니터링할 필요가 있다.

Keywords

References

  1. World Health Organization. WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: World Health Organization; 2021 [cited 2022 May 11]. Available from: https://covid19.who.int.
  2. Centers for Disease Control and Prevention. COVID data tracker [Internet]. Atlanta: Centers for Disease Control and Prevention; 2021 [cited 2022 Apr 20]. Available from: https://covid.cdc.gov/covid-datatracker/#demographicsovertime.
  3. World Health Organization. COVID-19 vaccine tracker and landscape [Internet]. Geneva: World Health Organization; 2021 [cited 2022 May 25]. Available from: https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines.
  4. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23. https://doi.org/10.1056/NEJMoa2101765
  5. Centers for Disease Control and Prevention. The coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network [Internet]. Atlanta: Centers for Disease Control and Prevention; 2021 [cited 2022 Jun 1]. Available from: https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html.
  6. American Academy of Pediatrics. Children and COVID-19: state-level data report [Internet]. Itasca: American Academy of Pediatrics; 2021 [cited 2022 May 3]. Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report.
  7. European Centre for Disease Prevention and Control. COVID-19 in children and the role of school settings in transmission - second update [Internet]. Solna: European Centre for Disease Prevention and Control; 2021 [cited 2022 Jun 30]. Available from: https://www.ecdc.europa.eu/en/publications-data/children-andschool-settings-covid-19-transmission.
  8. Delahoy MJ, Ujamaa D, Whitaker M, O'Halloran A, Anglin O, Burns E, et al. Hospitalizations associated with COVID-19 among children and adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1255-60. https://doi.org/10.15585/mmwr.mm7036e2
  9. VIPER Group COVID19 Vaccine Tracker Team. COVID-19 vaccine tracker [Internet]. [place unknown]: VIPER Group COVID19 Vaccine Tracker Team; 2021 [cited 2022 May 3]. Available from: https://covid19.trackvaccines.org.
  10. World Health Organization. COVID-19 vaccines, WHO's emergency use listing [Internet]. Geneva: World Health Organization; 2021 [cited 2022 May 4]. Available from: https://extranet.who.int/pqweb/vaccines/covid-19-vaccines.
  11. U.S Food & Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic [Internet]. Silver Spring: U.S Food & Drug Administration; 2021 [cited 2022 May 4]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccineemergency-use.
  12. European Medicines Agency. First COVID-19 vaccine approved for children aged 12 to 15 in EU [Internet]. Amsterdam: European Medicines Agency; 2021 [cited 2022 May 5]. Available from: https://www.ema. europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu.
  13. Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022;377:e069989.
  14. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis 2022;9:ofac138.
  15. Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: a systematic review and metaanalysis. Int Immunopharmacol 2022;109:108906.
  16. Haas JW, Bender FL, Ballou S, Kelley JM, Wilhelm M, Miller FG, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Netw Open 2022;5:e2143955.
  17. Lee AS, Balakrishnan ID, Khoo CY, Ng CT, Loh JK, Chan LL, et al. Myocarditis following COVID-19 vaccination: a systematic review (October 2020-October 2021). Heart Lung Circ 2022;31:757-65. https://doi.org/10.1016/j.hlc.2022.02.002
  18. Park DY, An S, Kaur A, Malhotra S, Vij A. Myocarditis after COVID-19 mRNA vaccination: a systematic review of case reports and case series. Clin Cardiol 2022;45:691-700. https://doi.org/10.1002/clc.23828
  19. Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: a systematic review of randomized controlled trials. J Med Virol 2022;94:4644-53. https://doi.org/10.1002/jmv.27940
  20. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty 2021;10:94.
  21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
  22. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019;10:ED000142.
  23. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley & Sons, 2019.
  24. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med 2021;385:2241-51. https://doi.org/10.1056/NEJMoa2109522
  25. Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med 2021;385:239-50. https://doi.org/10.1056/NEJMoa2107456
  26. Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the emergence of the Omicron variant. medRxiv, in press 2022.
  27. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance. JAMA 2022;327:2210-9. https://doi.org/10.1001/jama.2022.7493
  28. Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis 2021;27:2919-22. https://doi.org/10.3201/eid2711.211886
  29. Husin M, Tok PS, Suah JL, Thevananthan T, Tng BH, Peariasamy KM, et al. Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia. Int J Infect Dis 2022;121:55-7. https://doi.org/10.1016/j.ijid.2022.04.053
  30. Choe YJ, Yi S, Hwang I, Kim J, Park YJ, Cho E, et al. Safety and effectiveness of BNT162b2 mRNA COVID-19 vaccine in adolescents. Vaccine 2022;40:691-4. https://doi.org/10.1016/j.vaccine.2021.12.044
  31. Lai FT, Chua GT, Chan EW, Huang L, Kwan MY, Ma T, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect 2022;11:885-93.
  32. Li X, Lai FT, Chua GT, Kwan MY, Lau YL, Ip P, et al. Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr 2022;176:612-4. https://doi.org/10.1001/jamapediatrics.2022.0101
  33. Nygaard U, Holm M, Bohnstedt C, Chai Q, Schmidt LS, Hartling UB, et al. Population-based incidence of myopericarditis after COVID-19 vaccination in Danish adolescents. Pediatr Infect Dis J 2022;41:e25-8.  https://doi.org/10.1097/INF.0000000000003389
  34. Oliveira CR, Niccolai LM, Sheikha H, Elmansy L, Kalinich CC, Grubaugh ND, et al. Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents.JAMA Netw Open 2022;5;e220935. 
  35. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNAbased COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022;327:331-40.  https://doi.org/10.1001/jama.2021.24110
  36. Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Reg Health Eur 2022;17:100393.
  37. Powell AA, Kirsebom F, Stowe J, McOwat K, Saliba V, Ramsay ME, et al. Effectiveness of BNT162b2 against COVID-19 in adolescents. Lancet Infect Dis 2022;22:581-3. https://doi.org/10.1016/S1473-3099(22)00177-3
  38. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 protection against the Omicron variant in children and adolescents. N Engl J Med 2022;30:30.
  39. Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. medRxiv, in press 2022.
  40. Kim ST, Hwang IS, Go MJ, Kim HJ, Park KE, Cho SY, et al. Status of adverse reaction monitoring after COVID-19 vaccination in children and adolescents (12 to 17 years old).Public Health Wkly Rep 2021;14:3542-8.
  41. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med 2021;385:2132-9. https://doi.org/10.1056/NEJMoa2110737
  42. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977-82.  https://doi.org/10.15585/mmwr.mm7027e2
  43. Hwang IS, Song JS, Seo SY, Kim Y, Lee YK, et al.Status of adverse reactions after COVID-19 vaccination in third-year high school students. Public Health Wkly Rep 2021;14:2796-802.
  44. National Library of Medicine. ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine; 2021 [cited 2022 May 10]. Available from: https://clinicaltrials.gov/ct2/results?cond=covid-19+vaccines&age_v=&age=0&gndr=&type=&rslt=&phase=2&phase=3&Search=Apply.
  45. Pfizer. Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years [Internet]. New York: Pfizer; 2021 [cited 2022 Jun 3]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results.
  46. Committee on Infectious Diseases. COVID-19 vaccines in children and adolescents. Pediatrics 2021;148:e2021052336.
  47. Public Health Agency of Canada. National Advisory Committee on Immunization. mRNA COVID-19 vaccines in adolescents 12 to 17 years of age: NACI recommendation [Internet]. Ottawa: Public Health Agency of Canada; 2021 [cited 2022 May 8]. Available from: https://www.canada.ca/en/public-health/ services/immunization/national-advisory-committee-on-immunization-naci/recommendations-usecovid-19-vaccines/mrna-adolescents.html.
  48. European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU [Internet]. Amsterdam: European Medicines Agency; 2021 [cited 2022 May 11]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu.
  49. Ministerial Correspondence and Public Enquiries Unit, Department of Health and Social Care. JCVI statement on COVID-19 vaccination of children aged 12 to 15 years: 3 September 2021 [Internet]. London: Ministerial Correspondence and Public Enquiries Unit, Department of Health and Social Care; 2021 [cited 2022 May 11]. Available from: https://www.gov.uk/government/publications/jcvi-statement-september2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-ofchildren-aged-12-to-15-years-3-september-2021.
  50. Ministry of Food and Drug Safety. MFDS expands the vaccination age for Pizer COVID-19 vaccine [Press Release, July 16, 2021]. Cheongju: Ministry of Food and Drug Safety, 2021.
  51. Korea Diseases Control and Prevention Agency. Updates on COVID-19 in Republic of Korea (as of 3 October 2021). Cheongju: Korea Diseases Control and Prevention Agency, 2021.
  52. European Centre for Disease Prevention and Control. Questions and answers on COVID-19: vaccines [Internet]. Solna: European Centre for Disease Prevention and Control; 2021 [cited 2022 May 11]. Available from: https://www.ecdc.europa.eu/en/covid-19/questions-answers/questions-and-answers-vaccines.